EGFR and neoplasm: Furthermore, it has been recently shown how mutations in the epidermal growth factor receptor (EGFR) lead to GB-derived PCs to control pro-tumor responses, supporting previous findings indicating that both vascular and immune TME facilitate tumor growth [54].